title: Nutritional status and lipid profile of HIV-positive children and adolescents using antiretroviral therapy.
abstract: OBJECTIVE
  To describe nutritional status, body composition and lipid profile in children and adolescents receiving protease inhibitors.
  
  
  METHODS
  Fifty-nine patients, 23 treated with protease inhibitors (group 1) and 36 not using protease inhibitors (group 2). Their dietary intake, anthropometry, bioimpedance analysis and lipid profile variables were measured.
  
  
  RESULTS
  There was no difference in nutritional status or body composition between groups at the beginning of the study. After 6 months of follow-up, there was an increase in weight and height in both groups, as well as in waist circumference and subscapular skinfold thickness. In group 2, body mass index and triceps skinfold thickness adequacy were significantly higher after 6 months of follow-up. The groups had similar energy and macronutrient intake at any time point. After 6 months, group 1 had a higher cholesterol intake and group 2 had a higher fiber intake. Triglyceride serum levels were significantly different between the groups, with higher values in G1, at any time point [G1: 153 mg/dl (30-344); 138 (58-378) versus G2: 76 mg/dl (29-378); 76 (29-378)]. After 6 months of follow-up, G1 had higher LDL-cholesterol than G2 [104 mg/dl (40-142) versus 82 (42-145)].
  
  
  CONCLUSIONS
  The use of protease inhibitors, per se, does not seem to significantly interfere with anthropometric measures, body composition and food intake of HIV-infected children and adolescents. However, this antiretroviral therapy was associated with a significant increase in triglyceride and LDL-cholesterol in our subjects.
authors.affiliation: Nutrition and Metabolism, Medical School of Ribeirão Preto, University of São Paulo Department of Pediatrics, Ribeirão Preto, São Paulo, Brazil. patriciacontri@yahoo.com.br
authors.forename: Patricia Viganó
authors.initials: PV
authors.lastname: Contri
authors.forename: Erica Miranda
authors.initials: EM
authors.lastname: Berchielli
authors.forename: Marina Hjertquist
authors.initials: MH
authors.lastname: Tremeschin
authors.forename: Bento Vidal de Moura
authors.initials: BV
authors.lastname: Negrini
authors.forename: Roberta Garcia
authors.initials: RG
authors.lastname: Salomão
authors.forename: Jacqueline Pontes
authors.initials: JP
authors.lastname: Monteiro
mesh_terms: D000293:Adolescent; D000886:Anthropometry; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001823:Body Composition / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D002149:Energy Intake / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D009752:Nutritional Status / Q000187:drug effects*; D012307:Risk Factors; D018709:Statistics, Nonparametric; D013997:Time Factors
chemical_list: D017320:HIV Protease Inhibitors; D008055:Lipids